GlassScriptPhysician profile
Heather L Bailey
NPI 1417058298
$2,934.49
in general payments reported to CMS, 2019-2025
34 companies · $823 in 2025
The $823 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $705 · 2022: $559 · 2023: $507 · 2024: $340 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $378.82 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $263.89 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $236.88 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $187.23 | 2021-2025 | |
| Abbvie INC. | $179.15 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $156.18 | 2021-2025 | Verquvo, Capvaxive, Vaxneuvance |
| Lilly USA, LLC | $151.06 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.06 | 2024-2025 | Caplyta |
| Abbott Laboratories | $103.76 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $103.48 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.97 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $87.08 | 2021-2022 | |
| Amarin Pharma, INC. | $86.02 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $84.51 | 2021-2023 | |
| Biogen, INC. | $62.64 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58.86 | 2022-2023 | Injectafer |
| Amgen INC. | $55.08 | 2022-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $50.69 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $47.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.21 | 2023 | Trintellix |
| Exact Sciences Corporation | $42.94 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $37.55 | 2022 | |
| Phathom Pharmaceuticals, INC. | $36.87 | 2025 | Voquezna |
| Astellas Pharma US INC | $36.29 | 2021 | |
| Edwards Lifesciences Corporation | $35.04 | 2025 | |
| Corcept Therapeutics | $33.18 | 2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $27.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.48 | 2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $22.03 | 2022 | |
| Sumitomo Pharma America, INC. | $21.29 | 2025 | Gemtesa |
| Dexcom, INC. | $20.94 | 2021 | |
| Scpharmaceuticals INC. | $17.28 | 2025 | |
| Vistapharm, INC. | $14.90 | 2021 | |
| Eisai INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.